Actavis expands the world's only pharmaceutical manufacturing facility completely powered by renewable energy
(Thomson Reuters ONE) -
- Zero carbon footprint for tablet manufacturing and packaging
Reykjavik, Iceland, 14 January 2011 - Actavis Group, the world's fourth largest
generic pharmaceutical company, today formally opened a new expansion to its
pharmaceutical manufacturing site in Iceland. Powered solely by geothermal
energy, giving it a zero carbon footprint for tablet manufacturing and
packaging, the site uses no fossil fuels. The facility is fully accredited to
supply the EU market.
The opening ceremony was attended by the President of Iceland, Olafur Ragnar
Grimsson and members of parliament.
Claudio Albrecht, CEO Actavis:
"The site is 100% powered by geothermal energy, and is therefore the most eco-
friendly pharmaceutical facility in the world. It meets both the ISO14001
environmental standard and the OHSAS18001 health- and safety standard,
reflecting the strong Environment, health and safety commitment of our company.
This latest investment increases the production capacity in Iceland by 50%,
giving us a significantly increased launch capability for the EU market. This is
our principal development and launch site for Europe. We're proud to be able
create jobs in Iceland by expanding this site."
Following the expansion the production capacity of the Hafnarfjordur, Iceland
site is about 1.5 billion tablets, around 96% of which are exported to the
European markets. The Group's investment on the expansion is about EUR 8M.
Actavis operates 14 manufacturing sites in 12 different countries: US, Bulgaria,
Iceland, China, Italy, India, Indonesia, Malta, Romania, Russia, Serbia, and the
UK. The Group's total production capacity is the equivalent of about 24bn
tablets.
Enquiries
Frank Staud
Executive Vice President - Corporate Communications
Tel: +41 79 2309 578
E-mail: fstaud(at)actavis.com
Hjordis Arnadottir
Director - External Communications
Tel: +354 840 7476 / +41 79 909 7336
E-mail:harnadottir(at)actavis.com
About Actavis Group
Actavis is one of the world's leading generic pharmaceutical companies
specializing in the development, manufacture and sale of generic
pharmaceuticals. The company has operations in more than 40 countries, with
10,000 employees. For further information on Actavis Group, please visit
www.actavis.com
Any statements contained in this press release that refer to Actavis' estimated
or anticipated future results or future activities are forward-looking
statements which reflect the Company's current analysis of existing trends,
information and plans. These forward-looking statements are subject to a number
of risks and uncertainties that could cause actual results to differ materially
depending on factors such as the availability of resources, the timing and
effect of regulatory actions, the success of new products, the strength of
competition, the success of research and development issues, unexpected contract
breaches or terminations, exposure to product liability and other lawsuits, the
effect of currency fluctuations and other factors.
Photo geothermal, Reykjanes, Iceland:
http://hugin.info/134004/R/1479800/415418.jpg
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Actavis via Thomson Reuters ONE
[HUG#1479800]
Unternehmensinformation / Kurzprofil:
Datum: 14.01.2011 - 11:30 Uhr
Sprache: Deutsch
News-ID 50458
Anzahl Zeichen: 4029
contact information:
Town:
Hafnarfjordur
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 195 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Actavis expands the world's only pharmaceutical manufacturing facility completely powered by renewable energy"
steht unter der journalistisch-redaktionellen Verantwortung von
Actavis (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
